CD47-SIRPα Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Nonsmall Cell Lung Cancer

CD47 is a cell surface protein in the immunoglobulin superfamily which is normally expressed at low levels in every healthy cell. It´s main physiologic function is to act as an inhibitor of phagocytosis; this occurs throughout interaction with SIRPa expressed on macrophages. Interaction between CD47...

Full description

Saved in:
Bibliographic Details
Main Authors: Rodrigo Catalán, Mario Orozco-Morales, Norma Y. Hernández-Pedro, Alberto Guijosa, Ana L. Colín-González, Federico Ávila-Moreno, Oscar Arrieta
Format: Article
Language:English
Published: Wiley 2020-01-01
Series:Journal of Immunology Research
Online Access:http://dx.doi.org/10.1155/2020/9435030
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849395319305928704
author Rodrigo Catalán
Mario Orozco-Morales
Norma Y. Hernández-Pedro
Alberto Guijosa
Ana L. Colín-González
Federico Ávila-Moreno
Oscar Arrieta
author_facet Rodrigo Catalán
Mario Orozco-Morales
Norma Y. Hernández-Pedro
Alberto Guijosa
Ana L. Colín-González
Federico Ávila-Moreno
Oscar Arrieta
author_sort Rodrigo Catalán
collection DOAJ
description CD47 is a cell surface protein in the immunoglobulin superfamily which is normally expressed at low levels in every healthy cell. It´s main physiologic function is to act as an inhibitor of phagocytosis; this occurs throughout interaction with SIRPa expressed on macrophages. Interaction between CD47 and SIRPa leads to activation of tyrosine phosphatases that inhibit myosin accumulation at the submembrane assembly site of the phagocytic synapse, resulting in phagocytosis blockade. In this way CD47 acts as a “don´t eat me signal” for healthy self-cells; accordingly, loss of CD47 leads to phagocytosis of aged or damaged cells. Taking advantage of this anti-phagocytic signal provided by CD47, many types of tumors overexpress this protein, thereby avoiding phagocytosis by macrophages and aiding in the survival of cancer cells. The aim of this review is to describe the physiologic the pathophysiologic role of CD47; summarize the available high-quality information about this molecule as a potential biomarker and/or therapeutic target in cancer; finally, we present an in-depth analysis of the available information about CD47 in association with nonsmall cell lung cancer, EGFR mutations, and tumor microenvironment.
format Article
id doaj-art-aae5d036e1e54e1bb06d0cb47eecf8f5
institution Kabale University
issn 2314-8861
2314-7156
language English
publishDate 2020-01-01
publisher Wiley
record_format Article
series Journal of Immunology Research
spelling doaj-art-aae5d036e1e54e1bb06d0cb47eecf8f52025-08-20T03:39:40ZengWileyJournal of Immunology Research2314-88612314-71562020-01-01202010.1155/2020/94350309435030CD47-SIRPα Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Nonsmall Cell Lung CancerRodrigo Catalán0Mario Orozco-Morales1Norma Y. Hernández-Pedro2Alberto Guijosa3Ana L. Colín-González4Federico Ávila-Moreno5Oscar Arrieta6Thoracic Oncology Unit, Instituto Nacional de Cancerología, Mexico City, MexicoLaboratory of Personalized Medicine, Instituto Nacional de Cancerología, Mexico City, MexicoLaboratory of Personalized Medicine, Instituto Nacional de Cancerología, Mexico City, MexicoLaboratory of Personalized Medicine, Instituto Nacional de Cancerología, Mexico City, MexicoLaboratory of Personalized Medicine, Instituto Nacional de Cancerología, Mexico City, MexicoLung Diseases and Cancer Epigenomics Laboratory, Biomedicine Research Unit (UBIMED), Facultad de Estudios Superiores (FES) Iztacala, Universidad Nacional Autónoma de Mexico (UNAM), Mexico State, MexicoThoracic Oncology Unit, Instituto Nacional de Cancerología, Mexico City, MexicoCD47 is a cell surface protein in the immunoglobulin superfamily which is normally expressed at low levels in every healthy cell. It´s main physiologic function is to act as an inhibitor of phagocytosis; this occurs throughout interaction with SIRPa expressed on macrophages. Interaction between CD47 and SIRPa leads to activation of tyrosine phosphatases that inhibit myosin accumulation at the submembrane assembly site of the phagocytic synapse, resulting in phagocytosis blockade. In this way CD47 acts as a “don´t eat me signal” for healthy self-cells; accordingly, loss of CD47 leads to phagocytosis of aged or damaged cells. Taking advantage of this anti-phagocytic signal provided by CD47, many types of tumors overexpress this protein, thereby avoiding phagocytosis by macrophages and aiding in the survival of cancer cells. The aim of this review is to describe the physiologic the pathophysiologic role of CD47; summarize the available high-quality information about this molecule as a potential biomarker and/or therapeutic target in cancer; finally, we present an in-depth analysis of the available information about CD47 in association with nonsmall cell lung cancer, EGFR mutations, and tumor microenvironment.http://dx.doi.org/10.1155/2020/9435030
spellingShingle Rodrigo Catalán
Mario Orozco-Morales
Norma Y. Hernández-Pedro
Alberto Guijosa
Ana L. Colín-González
Federico Ávila-Moreno
Oscar Arrieta
CD47-SIRPα Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Nonsmall Cell Lung Cancer
Journal of Immunology Research
title CD47-SIRPα Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Nonsmall Cell Lung Cancer
title_full CD47-SIRPα Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Nonsmall Cell Lung Cancer
title_fullStr CD47-SIRPα Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Nonsmall Cell Lung Cancer
title_full_unstemmed CD47-SIRPα Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Nonsmall Cell Lung Cancer
title_short CD47-SIRPα Axis as a Biomarker and Therapeutic Target in Cancer: Current Perspectives and Future Challenges in Nonsmall Cell Lung Cancer
title_sort cd47 sirpα axis as a biomarker and therapeutic target in cancer current perspectives and future challenges in nonsmall cell lung cancer
url http://dx.doi.org/10.1155/2020/9435030
work_keys_str_mv AT rodrigocatalan cd47sirpaaxisasabiomarkerandtherapeutictargetincancercurrentperspectivesandfuturechallengesinnonsmallcelllungcancer
AT marioorozcomorales cd47sirpaaxisasabiomarkerandtherapeutictargetincancercurrentperspectivesandfuturechallengesinnonsmallcelllungcancer
AT normayhernandezpedro cd47sirpaaxisasabiomarkerandtherapeutictargetincancercurrentperspectivesandfuturechallengesinnonsmallcelllungcancer
AT albertoguijosa cd47sirpaaxisasabiomarkerandtherapeutictargetincancercurrentperspectivesandfuturechallengesinnonsmallcelllungcancer
AT analcolingonzalez cd47sirpaaxisasabiomarkerandtherapeutictargetincancercurrentperspectivesandfuturechallengesinnonsmallcelllungcancer
AT federicoavilamoreno cd47sirpaaxisasabiomarkerandtherapeutictargetincancercurrentperspectivesandfuturechallengesinnonsmallcelllungcancer
AT oscararrieta cd47sirpaaxisasabiomarkerandtherapeutictargetincancercurrentperspectivesandfuturechallengesinnonsmallcelllungcancer